Veracyte, Inc. Expands Operations Campus-Research Laboratory In South San Francisco, California
01/08/2016
The company secured at 10-year lease with plans to accommodate new, state-of-the art R&D and CLIA laboratories, as well as offices for the approximately 120 employees based in the company's corporate location. To accommodate future growth, the company also secured expansion rights, enabling it to procure additional square footage in the same building during 2017 and 2019 as needed.
The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.
"This expansion is a direct reflection of Veracyte's success in executing against our business goals," said Bonnie Anderson, Veracyte's President/CEO. "Test volume for our lead product, the Afirma Gene Expression Classifier, increased significantly in 2015, as a result of multiple factors, including expanded reimbursement and inclusion in key industry guidelines.”
“Additionally, we successfully launched the Percepta Bronchial Genomic Classifier last April, and we plan to introduce a second pulmonology product later this year. This significant product growth and expansion has increased our need for additional lab space and employees, while further validating our core mission,” she added.
Most Read
-
-
Supply Chain Bottlenecks Creating New “Logistical Hotspots”
Q3 2021
-
The “Great Resignation” Is Impacting Corporate Relocations
Workforce Q4 2021
-
Changes in the Incentives Landscape
Q3 2021
-
2020 Top States for Doing Business Showcase Their Pro-Business Environments
Q3 2020
-
2021 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2021
-
How an International Business Can Enter the U.S. Market Via M&A
Q4 2021